KemPharm (NASDAQ:KMPH) has been assigned a $11.00 price objective by equities research analysts at Canaccord Genuity in a note issued to investors on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity’s price target indicates a potential upside of 83.33% from the stock’s current price.
Other analysts have also issued research reports about the stock. ValuEngine lowered shares of KemPharm from a “hold” rating to a “sell” rating in a report on Friday. Zacks Investment Research lowered shares of KemPharm from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. Finally, Royal Bank of Canada set a $9.00 price target on shares of KemPharm and gave the company a “buy” rating in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. KemPharm has a consensus rating of “Buy” and a consensus price target of $9.15.
Shares of KemPharm (NASDAQ:KMPH) opened at $6.00 on Friday. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. The firm has a market cap of $77.13, a P/E ratio of -2.27 and a beta of -0.08. KemPharm has a fifty-two week low of $2.45 and a fifty-two week high of $7.15.
Hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. boosted its stake in KemPharm by 26.7% in the fourth quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after acquiring an additional 34,114 shares during the last quarter. C WorldWide Group Holding A S boosted its stake in KemPharm by 14.1% in the third quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after acquiring an additional 53,829 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in KemPharm by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after acquiring an additional 17,721 shares during the last quarter. 36.33% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Analysts Give KemPharm (KMPH) a $11.00 Price Target” was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://weekherald.com/2018/02/24/canaccord-genuity-analysts-give-kempharm-kmph-a-11-00-price-target.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.